The Impact of Salt Intake on Sodium in the Skin and Inflammatory Skin Disease
Eligible age
18+ yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
Yes
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The goal of this clinical trial is to demonstrate the feasibility of a trial that examines the impact of changes in dietary sodium intake on skin sodium levels, atopic dermatitis, and psoriasis. In addition, it aims to generate preliminary data to begin to answer the following questions: 1. Is there an association between skin sodium concentration and atopic dermatitis and psoriasis severity? 2. Are changes in dietary sodium are associated with changes in skin sodium concentration and atopic dermatitis and psoriasis severity? Researchers will compare sodium tablets to a placebo (a look-alike substance that contains no drug) to specifically examine the impact of altering sodium intake. Participants will: * Follow a low-salt diet for the duration of the 13-week study * Take sodium chloride tablets every day for 5 weeks followed by a placebo every day for 5 weeks after a 2-week washout period, or vice versa * Visit the clinic up to 4 times to answer questionnaires, provide bio samples, complete dietary recalls, and undergo non-contrast sodium MRI
Sponsor: University of California, San Francisco
You may qualify if…
- ✓ Participants ages 18 years
- ✓ Willing and able to undergo non-contrast MRI.
You may not qualify if…
- ✕ Contraindications to MRI (such as cardiac pacemakers, claustrophobia, non-compatible intracranial vascular clips, IUDs, or other implants)
- ✕ A cardiac event in the past 6 months
- ✕ Impaired function of the liver or kidney (glomerular filtration rate \<60 mL/min)
- ✕ Medications that influence sodium excretion (e.g., diuretics or SGLT2 inhibitors)
- ✕ Antibiotic or immunomodulatory medications within the last month
- ✕ Contraindications to sodium tablets
- ✕ (Topical medications used exclusively on the head/neck or hands/feet (e.g., antifungal nail treatment, antidandruff shampoo, acne cleansers) are acceptable. Topical and systemic eczema treatments are acceptable if the participant has been on a stable dose for at least 2 months and still meets the severity entry criteria. Patients on dupilumab will not be excluded if they have been on dupilumab for at least two months and still meet the disease severity inclusion criteria.)
Where it's recruiting
San Francisco
Source: ClinicalTrials.gov · NCT07487831 · last updated 2026-09-09